. Author manuscript; available in PMC: 2013 May 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2011 Sep 29;18(5):739–746. doi: 10.1016/j.bbmt.2011.09.008

Table 3.

Multivariate analysis of clinical outcomes by HistoCheck DSS score quartile groups and treated as a continuous variable

Outcome	Group 1 DSS 1.04 – 2.84^a	Group 2 DSS >2.84 – 13.75 RR (95% CI)	Group 3 DSS >13.75 – 19.39 RR (95% CI)	Group 4 DSS >19.39 – 36.62 RR (95% CI)	Overall P-value	DSS Continuous P-value
Acute GVHD II-IV	1.00	1.06 (0.79 – 1.41)	1.05 (0.79 – 1.39)	1.16 (0.88 – 1.54)	0.78	0.50
Chronic GVHD	1.00	0.86 (0.61 – 1.21)	0.82 (0.59 – 1.14)	0.97 (0.69 – 1.37)	0.61	0.89
Treatment-related mortality	1.00	1.22 (0.91 – 1.63)	1.13 (0.84 – 1.51)	1.32 (0.98 – 1.77)	0.29	0.58
Relapse	1.00	1.47 (0.93 – 2.32)	0.99 (0.61 – 1.60)	1.44 (0.93 – 2.26)	0.14	0.34
Overall survival	1.00	1.25 (0.98 – 1.61)	1.07 (0.83 – 1.38)	1.28 (1.00 – 1.64)	0.14	0.57
Disease-free survival	1.00	1.30 (1.01 – 1.66)	1.11 (0.86 – 1.42)	1.35 (1.05 – 1.73)	0.06	0.45
Neutrophil engraftment^b	1.00	0.85 (0.41 – 1.75)	0.63 (0.32 – 1.25)	0.48 (0.25 – 0.95) 0.13	0.03

Reference group

Data reported as an odds ratio in favor of engraftment